Cara Therapeutics Inc. hit the primary endpoint and secondary endpoint along with multiple quality-of-life measures in the first of two Phase III trials for Korsuva, its intravenous therapy for moderate-to-severe pruritus in chronic kidney disease patients on dialysis. The company intends to discuss NDA filing plans with the US Food and Drug Administration later this year while awaiting data from a second pivotal trial.
Analysts called the top-line data from the 350-patient KALM-1 study unveiled on 29 May “a home run” and “significantly de-risking”...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)